Ten reasons for choosing bilastine in 2025 Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Mar 31, 2025
DOI: https://doi.org/10.24292/01.MF.0125.17
Keywords:
allergy, allergic rhinitis, bilastine

Main Article Content

Piotr Rapiejko
Klinika Otolaryngologii i Onkologii Laryngologicznej z Klinicznym Oddziałem Chirurgii Czaszkowo-Szczękowo-Twarzowej, Wojskowy Instytut Medyczny w Warszawie

Abstract

Bilastine is a novel non-sedating histamine H1-receptor antagonist developed for the treatment of allergic rhinoconjunctivitis and urticaria. Bilastine has a similar efficacy to other second-generation H1-receptor. Studies in human volunteers demonstrated that bilastine is rapidly absorbed after oral treatment, reaching maximal plasma concentrations 1–1.5 h after administration. The absorption of bilastine is linear and dose-proportional; it appears to be safe and well tolerated. Multiple administration of bilastine has confirmed the linearity of the kinetic parameters. The safety profile in terms of adverse effects is very similar to placebo. The distribution in the brain is undetectable. Bilastine 20 mg does not increase alcohol effects and is similar to placebo in the driving test. Bilastine is still the newest oral antihistamine in 2025, and after 15 years of use, we have a large number of new clinical trials and observational studies confirming its therapeutic efficacy and safety.

Article Details

How to Cite
Rapiejko, P. (2025). Ten reasons for choosing bilastine in 2025. Medycyna Faktow (J EBM), 18(1(66), 112-116. https://doi.org/10.24292/01.MF.0125.17
Issue
Vol 18 No 1(66) (2025)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 2001; 108(suppl.): S147-334.
2. Samoliński B, Arcimowicz M (eds.). Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Alergologia Polska. 2013; S1.
3. Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J. Allergy Clin. Immunol. 2011; 128(6): 1139-50.e4.
4. Criado PR, Criado RF, Maruta CW et al. Histamine, histamine receptors and antihistamines: new concepts. An Bras. Dermatol. 2010; 85: 195-210.
5. Tarchalska-Kryńska B. Leki przeciwhistaminowe – farmakodynamika i farmakokinetyka. In: Leki przeciwhistaminowe – Stanowisko Grupy Ekspertów Polskiego Towarzystwa Alergologicznego. Górski P, Grzelewska-Rzymowska I, Kruszewski J (eds.). Wyd. Sesja, Łódź 2002: 33-57.
6. Sadaba B, Ramon Azanza J, Gomez-Guiu A et al. Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria. Ther Clin Risk Manag. 2013; 9: 197-205.
7. Jauregizar N, de la Fuente L, Lucero ML et al. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet. 2009; 48(8): 543-54.
8. Kuna P, Bachert C, Nowacki Z et al. Bilastine International Working Group: Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy. 2009; 39(9): 1338-47.
9. Horak F, Zieglmayer P, Zieglmayer R et al. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res. 2010; 59(5): 391-8.
10. Corcostegui R, Labeaga L, Innerárity A et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs. 2006; 7: 219-31.
11. Rapiejko P, Lipiec A. Bilastyna w leczeniu alergicznego nieżytu nosa. Postęp Derm Alergol. 2014; XXXI(suppl. 2): s16-27.
12. Scaglione F. Safety profile of bilastine: 2nd generation H1-antihistamines. Eur Rev Med Pharmacol Sci. 2012; 16(14): 1999-2005.
13. Pawliczak R. Bezpieczeństwo nowych leków przeciwhistaminowych. Terapia. 2012; 4: 60-6.
14. Montoro J, Mullol J, Davila I et al. Bilastine and the central nervous system. J Investig Allergol Clin Immunol. 2011; 21(suppl. 3): 9-15.
15. García-Gea C, Clos S, Antonijoan RM et al. Crossover, randomised, double-blind, double-dummy, placebo and positive standard-controlled, unicenter clinical trial to assess the possible interaction on CNS effects between bilastine (20 mg and 80 mg) and alcohol (0.8 g/kg) after single simultaneous administration in healthy subjects. 20th Congress of the Spanish Clinical Pharmacology Society. Basic Clin Pharmacol Toxicol. 2006; 99(suppl. I): 30. Abstract EC13.
16. Bachert C, Kuna P, Sanquer F et al. Comparison of the efficacy and safety of bilastine 20 mg vs. desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009; 64: 158-65.
17. Brożek JL, Bousquet J, Agache I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines – 2016 revision. J Allergy Clin Immunol. 2017; 140(4): 950-8.
18. Church MK, Canonica GW, Kuna P; Delphi Study Group. An international Delphi study on the burden of allergic rhinoconjunctivitis and urticaria and the role of bilastine among current treatment options. Expert Rev Clin Immunol. 2023; 19(7): 813-20. http://doi.org/10.1080/1744666X.2023.2214729.
19. Canonica GW, Kuna P, Maurer M et al. Bilastine for the treatment of allergic rhinoconjunctivitis and urticaria: results from an international Delphi study. Drugs Context. 2024; 13: 2024-2-3. http://doi.org/10.7573/dic.2024-2-3.